Altheos Secures $20,000,000 Series A Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=caf5b918-43cf-4ea5-9aa2-8b2678485e56&Preview=1 -
Date
4/5/2010 -
Company Name
Altheos -
Mailing Address
400 Oyster Point Boulevard South San Francisco, CA 94080 -
Company Description
Altheos, Inc. was founded by two seasoned pharmaceutical executives, Dr. Henry H. Hsu and Dr. M. (Ken) Kengatharan who have extensive experience in rapid capital efficient drug development as well as financing and growth of early stage biopharmaceutical companies. -
Website
http://www.altheos.net -
Transaction Type
Venture Equity -
Transaction Amount
$20,000,000 -
Transaction Round
Series A -
Proceeds Purposes
The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor Altheos licensed from Japanese pharmaceutical company Asahi Kasei Pharma. The license also includes a series of highly active compounds (AK138 series) specifically for topical treatment for glaucoma. -
M&A Terms
-
Venture Investor
Bay City Capital -
Venture Investor
Novo A/S -
Venture Investor
Canaan Partners -
Venture Investor
Life Science Angels -
Venture Investor
Undisclosed
